- Adjusted EBITDA in Q1 was €475 million; sales fell 9% to €3.43 billion, with volumes down 2% and prices down 1%, and the adjusted EBITDA margin was 13.9%.
- Net income was €125 million and free cash flow €183 million.
- Evonik expects Q2 adjusted EBITDA of at least €550 million and confirms full-year adjusted EBITDA guidance of €1.7-2.0 billion.
- The war in the Middle East raised energy and raw-material costs, disrupted trade routes and prompted customer pre-buying since March with higher methionine prices; the Tailor Made program will cut 1,000 jobs and Michael Rauch became CFO effective May 1.
Key figures
Adjusted EBITDA was €475 million in Q1 2026; sales totaled €3.43 billion (‑9%), with volumes down 2% and prices down 1%; unfavorable exchange rates caused more than half the sales decline. Adjusted EBITDA margin fell 0.9 pp to 13.9%. Net income was €125 million (Q1 2025: €233 million) and free cash flow €183 million (previous year €195 million).
Market impacts and outlook
The war in the Middle East increased energy and raw‑material costs, disrupted trade routes and led to customer pre‑buying since March; methionine prices rose. Evonik expects Q2 adjusted EBITDA of at least €550 million (Q2 2025: €509 million), views Q2 as likely the strongest quarter and confirms full‑year adjusted EBITDA guidance of €1.7–2.0 billion.
Segment performance
Advanced Technologies sales declined 9% to €1.45 billion and adjusted EBITDA fell 17% to €241 million (margin 16.6% vs 18.2% prior year). Custom Solutions sales were €1.33 billion (‑7%) and adjusted EBITDA €227 million (‑12%, margin 17.0% vs 17.9% prior year).
Management and efficiency
Michael Rauch became CFO effective May 1 and will present himself at the AGM on June 3; Claus Rettig returns to focus on Asia‑Pacific. The Tailor Made efficiency program is in its third year and, together with other optimization measures, will eliminate about 1,000 jobs this year.
